Hepatocellular Carcinoma Development in Patients with Diabetes Mellitus: A Nationwide Case-Control Study

Dr. Ryosuke Tateishi1, Dr. Takeshi Matsumura2, Dr. Koji Uchino1, Dr. Naoto Fujiwara1, Dr. Takafumi Senokuchi2, Dr. Kazuyoshi Kon3, Dr. Takahiro SASako4, Dr. Makiko Tanai5, Dr. Takumi Kawaguchi6, Prof. Hiroshi Inoue7, Prof. Hirotaka Watada8, Dr. Naoto Kubota9, Prof. Hitoshi Shimano9, Prof. Shuichi Kaneko10, Prof. Etsuko Hashimoto5, Prof. Hiroshi Inoue9, Prof. Sumio Watanabe3, Prof. Goshi Shiota11, Dr. Kojiro Ueki12, Dr. Kosuke Kashiwabara13, Prof. Yutaka Matsuyama13, Dr. Hideo Tanaka14, Prof. Masato Kasuga15, Prof. Eiichi Araki2 and Prof. Kazuhiko Koike1. (1)Department of Gastroenterology, The University of Tokyo Graduate School of Medicine, (2)Department of Metabolic Medicine, Kumamoto University Faculty of Life Sciences, (3)Department of Gastroenterology, Juntendo University School of Medicine, (4)Department of Diabetes and Metabolic Diseases, The University of Tokyo Graduate School of Medicine, (5)Institute of Gastroenterology, Juntendo University, (6)Department of Medicine, Kurume University School of Medicine, (7)Metabolism and Nutrition Research Unit, Kanazawa University Institute for Frontier Science Initiative, (8)Department of Medicine, Metabolism and Endocrinology, Juntendo University School of Medicine, (9)Department of Internal Medicine, Metabolism and Endocrinology, Juntendo University, (10)Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, (11)Division of Molecular and Genetic Medicine, Institute of Regenerative Medicine and Biofunction, Graduate School of Medicine, Tottori University, (12)Diabetes and Metabolism Information Center, National Center for Global Health and Medicine, (13)Department of Biostatistics and Bioinformatics, The University of Tokyo Graduate School of Medicine, (14)Aichi Cancer Center Research Institute, (15)The Institute of Adult Disease, Asahi Life Foundation

Abstract Text

Background: Diabetes mellitus (DM) is a known risk factor for hepatocellular carcinoma (HCC) development. However, the incidence among DM patients is reported to be less than 0.1% per year, which is far below the threshold for surveillance. We aimed to investigate other risk factors for HCC development in Japanese DM patients.

Methods: We enrolled DM patients who were diagnosed as HCC from 2010 to 2015 and followed at teaching hospitals certified by both Japan Society of Hepatology and Japan Diabetes Society for at least five years before HCC diagnosis. Those with chronic viral hepatitis were excluded. Clinical data at the initial HCC diagnosis and those at 5-years before the diagnosis were collected via electronic data capture system. Age and gender-matched non-HCC controls were selected from a prospective cohort of Japanese DM patients with a follow-up period of 5 years at tertiary care hospitals at a 1:4 ratio. We investigated clinical characteristics of the HCC patients and analyzed risk factors for HCC development using conditional logistic regression. Fibrosis-4 (FIB-4) index was calculated and included for the analysis.

Results: A total of 264 HCC patients from 83 hospitals were registered in the database. The mean age was 72.8 ± 8.7 years, and 79.7% were males. The period from DM diagnosis and HCC diagnosis were 14.5 years on average. The BMI, fasting blood glucose, and HbA1c at five years before the diagnosis of HCC was 25.9 ± 4.5kg/m², 159.2 ± 56.8mg/dL, and 7.42 ± 1.46%, respectively. The BMI and HbA1c significantly decreased in 5 years. The FIB-4 index also increased significantly from 3.59 ± 2.70 to 4.79 ± 3.69. Multiple conditional logistic regression with 191 HCC patients and 764 controls without missing essential data revealed that higher BMI, lower albumin, higher GGT, higher FIB-4 index, and the presence of hypertension were significant risk factors for HCC development. Especially the hazard ratio between FIB-4 in the first quartile and the fourth quartile was 16.245 (95% confidence interval, 7.824–33.728; P < 0.0001). On the other hand, HbA1c and the presence of dyslipidemia were not significant.

Conclusion: In addition to previously-reported higher age and male gender, BMI and FIB-4 index can be used to identify a high-risk population for the HCC surveillance in DM patients.

Disclosures

Goshi Shiota – KanonCure Inc.: Stock Shareholder

The following people have nothing to disclose: Ryosuke Tateishi, Koji Uchino, Kazuyoshi Kon, Takahiro Sasako, Takumi Kawaguchi, Hirotaka Watada, Shuichi Kaneko, Etsuko Hashimoto, Sumio Watanabe, Kosuke Kashiwabara, Kazuhiko Koike

Disclosure information not available at the time of publication: Takeshi Matsumura, Naoto Fujiwara, Takafumi Senokuchi, Makiko Tanai, Hiroshi Inoue, Naoto Kubota, Hitoshi Shimano, Kojiro Ueki, Yutaka Matsuyama, Hideo Tanaka, Masato Kasuga, Eiichi Araki